Extracorporeal therapies are always associated with the risks of complications due to blood contact with foreign surfaces. Both the humoral and the blood cell systems are activated by the large foreign surface area of extracorporeal circuits. Various interactions of these systems may lead to systemic reactions of the patient. Improved haemocompatiblity of the biomaterials used can reduce these complications.
At present, the most promising and approved method to improve haemocompatibility is a heparin coating of the blood contacting surfaces. The RHEOPARIN®
coating was developed by MEDOS in order to improve the biomaterials particularly of extracorporeal circuits.
Applying a RHEOPARIN® coated extracorporeal system, the blood gets into contact with a more haemocompatible environment than in a conventional non treated system.
|
How do artificial surfaces profit from RHEOPARIN®?
MEDOS RHEOPARIN® represents a biomaterial coating applying a new developed ionic heparin bonding method for extracorporeal circuits which results in improved haemocompatibility of foreign surfaces.
Clinical benefit of RHEOPARIN® was proven in terms of following positiv effects on blood as for instance:
- RHEOPARIN® reduces the activation of the blood coagulation system
- RHEOPARIN® leads the less platelet drop compared to non-treated material
- No change of the leucozytes and no material induced change of the differential blood scale
|
|
